Core Insights - Vivos Inc. has been granted U.S. Patent No. 12,521,452 B2 for its innovative cancer treatment technology, specifically a radioactive thermogel suspension that enhances its Precision Radionuclide TherapyTM platform [1][2] Patent and Technology - The patent protects a novel thermosensitive PLGA-g-PEG hydrogel combined with yttrium-90 particles, allowing for precise, localized radiation delivery to solid tumors while minimizing damage to healthy tissue [2] - The gel remains injectable at room temperature and solidifies at body temperature, ensuring effective immobilization of the radiation source [2] Intellectual Property Developments - Vivos has received approval for its PRECISIONGEL™ trademark in the U.S. and New Zealand, and has filed a new patent application to further protect its hydrogel technology [3] - The new application covers the hydrogel's use as a carrier for various therapeutic agents, reinforcing the company's position in advanced hydrogel-based delivery systems [3] Strategic Vision - The CEO of Vivos Inc. emphasized that these milestones significantly enhance the company's intellectual property portfolio, supporting clinical progress and potential strategic partnerships [4] - The focus on building a strong IP position is aimed at driving shareholder value and enabling global commercial expansion [4] Company Overview - Vivos Inc. is a clinical-stage medical device company developing RadioGel® for human oncology and IsoPet® for veterinary applications, with IsoPet® already available in certified clinics across the nation [5]

Core Insights - RenovoRx, Inc. announced the acceptance of its abstract submission for the 2026 Society of Interventional Oncology Annual Scientific Meeting, highlighting its innovative targeted oncology therapies and the RenovoCath drug-delivery device [1][6] Group 1: Clinical Study Presentation - The clinical data abstract titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" will be presented by researchers including Dr. Christopher Laing [2] - The study aims to validate a real-time method for intra-arterial pressure monitoring during TAMP procedures using the RenovoCath device, potentially optimizing chemotherapy delivery in challenging tumors [4] Group 2: RenovoCath Overview - RenovoCath is FDA-cleared for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications in arteriography, preoperative occlusion, and chemotherapeutic drug infusion [5][7] - The device is part of RenovoRx's TAMP therapy platform, designed to enhance targeted therapeutic delivery while minimizing toxicities compared to systemic intravenous therapy [7] Group 3: Commercialization and Financials - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath, generating approximately $900,000 in revenue from sales in the first nine months of 2025 [8] - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [8] Group 4: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [9] - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, providing seven years of market exclusivity upon FDA approval [10]

The event featured a combination of expert-led didactic lectures and live case observations, providing participating physicians from across Asia with critical insights into clinical applications and techniques. By focusing on both theoretical knowledge and practical application, the Masterclass reinforced the importance of precision in clinical practice and facilitated the exchange of advanced methodology among regional specialists. This initiative highlights Baird Medical's enduring commitment to physicia ...

Core Insights - Autonomix Medical, Inc. is set to present final clinical data on its transvascular radiofrequency (RF) ablation approach for pain management in pancreatic adenocarcinoma at the Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases related to the nervous system [5] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5] - The initial application of this technology is aimed at treating pain, particularly in pancreatic cancer, which is known for causing severe pain without reliable treatment options [6] Clinical Presentation Details - The presentation titled "Pain Mitigation in Pancreatic Adenocarcinoma: A Final Analysis of Neurolysis via Transvascular Radiofrequency (RF) Ablation" has been accepted as an ePoster for the conference [2] - The ePoster will be presented by Dr. Clarke Wilkirson on February 6, 2026, during a dedicated session that includes a 10-minute presentation followed by a 5-minute discussion [3] Industry Context - The SIO Annual Scientific Meeting gathers leading clinicians, researchers, and innovators focused on advancing minimally invasive, image-guided therapies for cancer care [4] - The presentation at this conference highlights the potential of Autonomix's RF ablation approach to address significant unmet clinical needs in pain management for pancreatic cancer patients [4]

Group 1: Company Overview - Johnson & Johnson (NYSE: JNJ) is a prominent healthcare company with a diverse product range in pharmaceuticals, medical devices, and consumer health, competing with major players like Pfizer and Merck [1] - The company's current trading price is $224.44, with a recent increase of $2.95, marking a 1.33% rise [4] - JNJ's market capitalization is approximately $540.7 billion, with a trading volume of 6,976,710 shares [4] Group 2: Financial Outlook - Johnson & Johnson has projected sales between $100 billion and $101 billion for 2026, exceeding the Zacks Consensus Estimate of $98.5 billion, indicating strong growth potential [2][6] - The company expects adjusted earnings per share to range from $11.43 to $11.63, reflecting confidence in its financial performance [2][6] Group 3: Segment Performance - The Innovative Medicine segment is anticipated to grow despite the loss of exclusivity for Stelara, driven by products like Darzalex and Tremfya, along with new product launches [3] - The MedTech segment is also expected to experience stronger growth, although it may face challenges from China's volume-based procurement policies [3] Group 4: Stock Performance - Over the past year, JNJ's stock price has fluctuated between a low of $141.50 and its current high of $224.44, reflecting the dynamic nature of the healthcare industry [5] - Morgan Stanley has set a price target of $262 for JNJ, suggesting a potential upside of 16.73% from its current trading price [1][6]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, significantly below analysts' estimates, and projected poor net sales growth of -2% to 2% for 2026 [6]. - The stock price dropped by $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025, following the announcement [6].

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medical device mergers and acquisitions accelerated in the second half of 2025, propelled by several large deal announcements, according to a report released this month by Bain & Company. Medtech M&A brought in a total value of about $80 billion through Nov. 30, 2025, surpassing the previous three years. Much of the activity took place in the second half of the ye ...

Core Insights - The global Sensor Patch Market is transforming as healthcare systems adopt real-time, continuous, and remote patient monitoring models, making sensor patches integral to modern digital healthcare ecosystems [1][2] Market Drivers - The demand for accurate diagnostics, early disease detection, and personalized treatment approaches is driving the growth of the sensor patch market, with advancements in sensor technology and AI integration further accelerating adoption [2][5] - The rapid expansion of remote patient monitoring (RPM) has reshaped healthcare delivery models, with governments recognizing the value of continuous monitoring to improve care accessibility and clinical outcomes [3][4] - Nearly 60% of adults globally live with at least one chronic disease, increasing the demand for long-term monitoring solutions, supported by government-funded healthcare programs expanding reimbursement for RPM [4][5] Key Applications - Sensor patches are increasingly used in chronic disease management, particularly for diabetes, cardiovascular conditions, and respiratory disorders, offering continuous, high-resolution physiological data [5][6] - Key applications driving adoption include glucose monitoring for diabetes management, ECG patches for cardiac risk detection, respiratory monitoring for COPD and asthma, temperature monitoring for infection management, and sweat analysis for hydration monitoring [7][8] Regional Outlook - North America is the largest market for sensor patches, driven by high chronic disease burden and strong reimbursement coverage, while Asia-Pacific is experiencing the fastest growth due to large patient populations and government-led healthcare digitization initiatives [6][8] Competitive Landscape - Competition is shifting towards proving clinical performance and maintaining quality consistency, with key players including Abbott, Dexcom, and Medtronic leading in various segments [9][10] - Regulatory scrutiny is increasing, making reliability a competitive differentiator alongside innovation [9] Future Outlook - Sensor patches are evolving into intelligent health platforms, integrating AI algorithms for predictive analytics and enabling holistic patient assessments through multi-parameter tracking [12]

(GAAP)**|**20.40%**||**24.90%**||**12.00%**||**26.80%**||Full year 2025 impact from operating profit margins ofbusinesses that have been owned for less than one yearor were disposed of during such period and did notqualify as discontinued operations|(0.20)||—||(0.30)||(0.15)||Full year 2025 resolution of an acquisition contingency inthe Diagnostics segment|0.05||—||—||0.10||Full year 2025 impairment charges related to tradenames in the Life Sciences and Diagnostics segmentsand technology, other intangible a ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to alleged misleading statements made by the company during a specified class period [1]. Group 1: Class Action Details - Investors who purchased Integer common stock between July 25, 2024, and October 22, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Allegations Against Integer Holdings - The lawsuit claims that Integer Holdings made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is alleged that Integer overstated its visibility into customer demand and mischaracterized its electrophysiology devices as long-term growth drivers for its cardio and vascular segment, despite experiencing a deterioration in sales [5].